The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | TOPGEAR: preoperative therapy for gastric and gastroesophageal junction adenocarcinoma
Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses highlights from ESMO 2024, including the TOPGEAR trial which investigated the impact of adding radiotherapy to standard chemotherapy for patients undergoing surgery for gastric and gastroesophageal junction adenocarcinoma. The trial, which was conducted across multiple sites showed that while the addition of radiotherapy improved pathologic outcomes, it did not translate to improved long-term survival. Dr Elliott also emphasizes the importance of the patient advocacy track at ESMO 2024, highlighting the value of involving patients, carers and advocates in research. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
